Clinical Trial Update: Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of VIP-152 in combination with Venetoclax and Prednisone in relapsed/refractory lymphoid malignancies has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• PREDNISONE (Prednisone)
• VIP-152 (VIP-152)
• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-04-08